Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis by Leonidas Kandilogiannakis, Eirini Filidou, Ioannis Drygiannakis, Gesthimani Tarapatzi, Stylianos Didaskalou, Maria Koffa, Konstantinos Arvanitidis, Giorgos Bamias, Vassilis Valatas, Vasilis Paspaliaris, George Kolios

“…Epithelial and mesenchymal 2D cultures are highly utilized in vitro models for the preclinical evaluation of anti-inflammatory and antifibrotic therapies. …”
Get full text

Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy by Amaury Herbet, Marie Hautière, Frédéric Jean-Alphonse, Delphine Vivier, Christophe Leboeuf, Narciso Costa, Aloïse Mabondzo, Guilhem Bousquet, Franck Denat, Eric Reiter, Didier Boquet

“…We have characterized its physicochemical properties, studied its binding mechanisms, and evaluated its therapeutic potential in a preclinical model. Immunohistochemical analysis of metastatic melanoma lymph nodes evaluated RB49 as a diagnostic tool for patient stratification. …”
Get full text

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial by Jeffrey M. Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B. Nixon, Michael Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F. Patz

“…Abstract GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in refractory non-small cell lung cancer to assess the safety of GT103 (NCT04314089). …”
Get full text

Human Umbilical Cord Perivascular Cells Prevent Tumor Growth in a Melanoma Tumor-Bearing Mouse Model and Modulate Breast Cancer and Melanoma Cells in a Cell Line-Dependent Manner I... by Lianet Lopez, Hannah Shuster-Hyman, Eden Marco, Hasna Khan, Avishai Gasner, Aleksandra Uzelac, Brandon Wyse, Poonam Mander, Mugundhine Sangaralingam, Joseph Fish, Ariel Gorodensky, Samar Mouazz, Amanda Kauffman, Denis Gallagher, Andrée Gauthier-Fisher, Clifford L. Librach

“…Cancer cell- and donor-dependent paracrine effects on cancer cell growth were observed in vitro. Our preclinical studies thus suggest that, with regards to its effects on tumor growth, systemic administration of FTM and term human umbilical cord perivascular cells may be a safe cell therapy to address the side effects of cancer.…”
Get full text

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer by Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin

“…Despite widespread deregulation of CDK4/6 activity in non-small cell lung cancer (NSCLC), clinical trials with CDK4/6 inhibitor (CDK4/6i) as a monotherapy have shown poor antitumor activity. Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during radiotherapy. …”
Get full text

Genetic context modulates aging and degeneration in the murine retina by Olivia J. Marola, Michael MacLean, Travis L. Cossette, Cory A. Diemler, Amanda A. Hewes, Alaina M. Reagan, Jonathan Nyandu Kanyinda, Daniel A. Skelly, Gareth R. Howell

“…Our investigations identified and validated WSB and NZO mice as improved preclinical models relevant to common retinal neurodegenerative diseases.…”
Get full text

Hepatobiliary organoid research: the progress and applications by Rui-Qi Zou, Rui-Qi Zou, Yu-Shi Dai, Yu-Shi Dai, Fei Liu, Fei Liu, Si-Qi Yang, Si-Qi Yang, Hai-Jie Hu, Hai-Jie Hu, Fu-Yu Li, Fu-Yu Li

“…Consequently, it is widely used in basic and clinical studies, becoming important preclinical models for studying diseases and developing therapies. …”
Get full text

Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo by Wieslawa H. Dragowska, Jagbir Singh, Mohamed Wehbe, Malathi Anantha, Katarina Edwards, Sharon M. Gorski, Marcel B. Bally, Ada W. Y. Leung

“…<b>Background/Objectives:</b> Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. …”
Get full text

Induced mesenchymal stem cells generated from periodontal ligament fibroblast for regenerative therapy by Hemanathan Vembuli, Sheeja Rajasingh, Patrick Nabholz, Jefferson Guenther, Brian R. Morrow, Margaret M. Taylor, Marziyeh Aghazadeh, Vinoth Sigamani, Johnson Rajasingh, Johnson Rajasingh, Johnson Rajasingh

“…Stem cells derived from oral tissues and umbilical cord mesenchymal stem cells (MSCs) have shown potential in both preclinical and clinical studies for bone tissue regeneration. …”
Get full text

Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer by Claudia Duranti, Jessica Iorio, Valeria Manganelli, Giacomo Bagni, Rossella Colasurdo, Tiziano Lottini, Michele Martinelli, Chiara Capitani, Giulia Boso, Franco Nicolas D’Alessandro, Maurizio Sorice, Andrea Becchetti, Roberta Misasi, Tina Garofalo, Annarosa Arcangeli

“…Finally, the combined treatment with statins and scDb-hERG1-β1 significantly reduces tumor growth and improves survival in vivo, in a preclinical mouse model. These results suggest that the combination of scDb-hERG1-β1 and statins represent a potential novel strategy for treating PDAC patients.…”
Get full text

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening by Dan Zhao, Ravindra Deshpande, Kerui Wu, Abhishek Tyagi, Sambad Sharma, Shih-Ying Wu, Fei Xing, Stacey O'Neill, Jimmy Ruiz, Feng Lyu, Kounosuke Watabe

“…Importantly, the results of our preclinical experiments showed that inhibition of TUBB3 with a small molecule inhibitor synergized with anti-PD-1 treatment and enhanced tumor cell killing by cytotoxic T cells. …”
Get full text

YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma by Aránzazu Chamorro-Jorganes, Núria Profitós-Pelejà, Clara Recasens-Zorzo, Juan G Valero, Diana Reyes-Garau, Laura Magnano, Ray Butler, Antonio Postigo, Patricia Pérez-Galán, Marcelo Lima Ribeiro, Gaël Roué

“…Here we undertook the simultaneous evaluation of two epigenetic drugs targeting EZH2 methyltransferase activity and BRD4-mediated control of MYC transcription, CPI169 and CPI203, using preclinical models of DLBCL and FL with distinct EZH2 mutational status. …”
Get full text

Optical coherence tomography for examining retina in patients with HIV/TB coinfection by E.A. Burylova, A.P. Demin, S.N. Skornyakov, E.V. Sabadash

“…</i> </p> <p> <i><b>Conclusion</b>: OCT identifies changes in vessel diameter, central macular thickness, and peripapillary RFNL thickness before visual disturbances in preclinical eye changes in patients with HIV/TB coinfection.…”
Get full text

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses by Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman

“…In vivo antitumor efficacy was evaluated in syngeneic mouse models alone or in combination with programmed cell death protein-1 (PD-1) blockade. Preclinical safety, as well as pharmacodynamic (PD) and PK profiling was carried out in non-human primates.Results INBRX-120 effectively expanded and enhanced the cytotoxic capacity of CD8 T cells and natural killer cells towards tumor cells without affecting regulatory T cells in vitro and in vivo. …”
Get full text

Protection against SHIV-KB9 Infection by Combining rDNA and rFPV Vaccines Based on HIV Multiepitope and p24 Protein in Chinese Rhesus Macaques by Chang Li, Zhenwei Shen, Xiao Li, Jieying Bai, Lin Zeng, Mingyao Tian, Ying Jin Song, Ming Ye, Shouwen Du, Dayong Ren, Cunxia Liu, Na Zhu, Dandan Sun, Yi Li, Ningyi Jin

“…The present study contributes significantly to AIDS vaccine and preclinical research.…”
Get full text

Assessment of <i>Alternaria</i> Toxins and Pesticides in Organic and Conventional Tomato Products: Insights into Contamination Patterns and Food Safety Implications by Tommaso Pacini, Teresa D’Amore, Stefano Sdogati, Emanuela Verdini, Rita Bibi, Angela Caporali, Elisa Cristofani, Carmen Maresca, Serenella Orsini, Alessandro Pelliccia, Eleonora Scoccia, Ivan Pecorelli

Get full text

Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318 by Elaine M. Jagoda, Falguni Basuli, Colleen Olkowski, Ido Weiss, Tim E. Phelps, Karen Wong, Anita Thien Ton, Kelly C. Lane, Steve Adler, Donna Butcher, Elijah F. Edmondson, Sol Langermann, Peter L. Choyke

“…Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is overexpressed in various cancers which has led to the development of therapeutic anti-Siglec-15 monoconal antibodies (mAbs). In these preclinical studies, the therapeutic mAb, NC318 (antihuman/murine Siglec-15 mAb), was labeled with zirconium-89 and evaluated in human Siglec-15 expressing cancer cells and mouse xenografts for potential use as a clinical diagnostic imaging agent. …”
Get full text

Iron(III)&ndash;Quercetin Complex: In Vivo Acute Toxicity and Biodistribution of Novel MRI Agent by Innuan P, Kongkarnka S, Thongtharb A, Kantapan J, Dechsupa N

“…These properties make IronQ a promising candidate for safe and effective MRI contrast enhancement.Purpose: This study aims to further the development of IronQ as an MRI contrast agent by investigating its biodistribution, pharmacokinetics, and acute toxicity in a preclinical animal model.Methods: The relaxivity of IronQ was measured in water and whole blood phantoms. …”
Get full text

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer by Xiaojie Chu, Seungmin Shin, Du-San Baek, Liyong Zhang, Alex Conard, Megan Shi, Ye-Jin Kim, Cynthia Adams, Maggie Hines, Xianglei Liu, Chuan Chen, Zehua Sun, Dontcho V. Jelev, John W. Mellors, Dimiter S. Dimitrov, Wei Li

“…This is a first reported ADC based on a fully human PSCA antibody and MMAE that is characterized in a xenograft murine model, which warrants further optimizations and investigations in additional preclinical tumor models, including prostate and other solid tumors.…”
Get full text

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

“…The combined targeting of anti-CD20 and anti-CD47 results in enhanced anti- tumor activity compared to anti-CD20 targeting antibodies alone. Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic properties with a favorable toxicity profile in non-human primates. …”
Get full text